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Inborn errors of the genes encoding two of the four human JAKs (JAK3 and TYK2) and three of the six human
STATs (STAT1, STAT3, and STAT5B) have been described.We review the disorders arising frommutations in
these five genes, highlighting the way in which the molecular and cellular pathogenesis of these conditions
has been clarified by the discovery of inborn errors of cytokines, hormones, and their receptors, including
those interacting with JAKs and STATs. The phenotypic similarities between mice and humans lacking indi-
vidual JAK-STAT components suggest that the functions of JAKs and STATs are largely conserved in
mammals. However, a wide array of phenotypic differences has emerged betweenmice and humans carrying
biallelic null alleles of JAK3, TYK2, STAT1, or STAT5B. Moreover, the high degree of allelic heterogeneity at
the human JAK3, TYK2, STAT1, and STAT3 loci has revealed highly diverse immunological and clinical
phenotypes, which had not been anticipated.None of the known Janus kinases (JAKs), or signal transducer
and activator of transcription (STAT) molecules, or associated
upstream receptors and downstream targets was discovered
through investigations of human patients (O’Shea et al., 2011).
Nevertheless, the discovery of germline mutations in the genes
encoding two of the four human JAKs (JAK3 and TYK2) and three
of the six human STATs (STAT1, STAT3, and STAT5B) has
provided considerable biological insight. The phenotypic similar-
ities between mice and humans lacking individual JAK-STAT
components suggest that the functions of JAKs and STATs are
largely conserved in mammals. However, a wide array of pheno-
typic differences has emerged between mice and humans with
defects in a single JAK-STAT component. Differences in immu-
nological phenotypes may reflect intrinsic mechanistic differ-
ences between the two species, as illustrated, for example, by
the insertion of a minisatellite into the mouse Stat2 gene, pre-
venting the recruitment of Stat4 in response to IFN-a and IFN-
b (Farrar et al., 2000). Differences in infectious phenotypes may
also reflect differences between experimental infections in mice
and natural infections in humans (Casanova and Abel, 2004).
We will review here the inborn errors affecting five human JAKs
and STATs, which mostly manifest as immunological and infec-
tious phenotypes, although extrahematological clinical features
have also been documented for at least two of these disorders
(STAT5B and STAT3 deficiency). We will specifically focus on
the biological lessons learned from these experiments of nature.
Human Severe Combined Immune Deficiency Reveals
a Critical Role for JAK3-Mediated Signaling in Lymphoid
Development and Function
In 1950, Glanzman and Riniker described two infants with severe
infections, diarrhea, and failure to thrive, both of whom died withdisseminated candidiasis. Postmortem examination revealed
a marked depletion of lymphoid tissue (Glanzmann and Riniker,
1950). These cases probably represent the first description of
severe combined immune deficiency (SCID) in humans, a genet-
ically heterogenous group of conditions characterized by a lack
of autologous T cells and extreme susceptibility to infections
caused by a broad range of pathogens. SCID is inevitably fatal
within the first few years of life, unless immune reconstitution
is achieved therapeutically (Gennery et al., 2010). The initial
descriptions of SCID were consistent with autosomal-recessive
(AR) inheritance, but it soon became clear that most of the
patients with SCID identified in the United States were male
(Gitlin and Craig, 1963) and that SCID was often inherited as
an X-linked recessive (XR) trait (Rosen et al., 1966). Patients
with XR SCID (X-SCID) typically lack circulating T and NK
lymphocytes but have normal numbers of B cells (TB+NK
SCID phenotype).
In 1992, Takeshita et al. (1992) cloned the IL2RG gene, encod-
ing the g chain of the interleukin-2 receptor (IL-2R). One year
later, Warren Leonard’s group mapped the IL2RG gene to
Xq13, where the X-SCID locus had been previously mapped,
and showed it to be mutated in patients with X-SCID (Table 1;
Figure 1; Noguchi et al., 1993b). The IL-2Rg chain was initially
defined as a component of the heterotrimeric high-affinity
IL-2R, which also includes IL-2Ra and IL-2Rb (Takeshita et al.,
1992). However, over the course of a decade, it was progres-
sively demonstrated that the IL-2Rg chain is common to the
receptors for IL-4, IL-7, IL-9, IL-15, and IL-21 (Kondo et al.,
1993; Russell et al., 1993; Noguchi et al., 1993a; Kimura et al.,
1995; Giri et al., 1994; Asao et al., 2001). This led to it being re-
named the common g chain, or gc. None of these cytokine
receptors has intrinsic kinase activity, and their ability to mediateImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 515
Table 1. Inborn Errors of Five Human JAKs and STATs and Their Related Defects
Gene Inheritance Allele Cytokines Hormones Disease Phenotype/Infections Type
JAK3 AR LOF, HPO IL-2, IL-4, IL-7, IL-9,
IL-15, IL-21
SCID T, B+, NK
IL-2RG XR LOF, HPO IL-2, IL-4, IL-7, IL-9,
IL-15, IL-21
SCID T, B+, NK
IL7R AR LOF IL-7 SCID T, B+, NK+
STAT5B AR LOF IL-2, IL-7, IL-15 GH CID, GHIS
IL2RA AR LOF IL-2 CID
GHR AR LOF GH GHIS
AD LOF GH GHIS
STAT1 AR LOF, HPO IFN-a and IFN-b, IFN-g,
IFN- l, IL-27
mycobacteria, viruses
AD LOF, HPO IFN-g mycobacteria DBD or TYD
IFNGR1 AR LOF, HPO IFN-g mycobacteria
AD LOF IFN-g mycobacteria
IFNGR2 AR LOF, HPO IFN-g mycobacteria
IRF8 AD HPO mycobacteria
IL12B AR LOF IL-12, IL-23 mycobacteria, salmonella, CMC
IL12RB1 AR LOF IL-12, IL-23 mycobacteria, salmonella, CMC
IKBKG XR HPO multiple mycobacteria
CYBB XR HPO mycobacteria
TYK2 AR LOF IFN-a and IFN-b, IFN-l,
IL-6, IL-10, IL-12, IL-23.
mycobacteria, salmonella,
viruses, Staphylococci, atopy*
IL12B AR LOF IL-12, IL-23 mycobacteria, salmonella, CMC
IL12RB1 AR LOF IL-12, IL-23 mycobacteria, salmonella, CMC
IL10 AR ? IL-10 colitis
IL10RB1 AR LOF IL-10 colitis
IL10RB2 AR LOF IL-10, IL-22, IFN-l colitis
STAT3 AD LOF IL-6, IL-10, IL-11, IL-21,
IL-23, etc.a
HIES*
IL11RA AR LOF IL-11 skull and teeth
IL17F AD HPO IL-17A/F, IL-17F/F CMC
IL17RA AR LOF IL-17A/A, IL-17A/F, IL-17F/F CMC
STAT1 AD HPR IFN-a and IFN-b, IFN-g,
IFN-l, IL-27b
CMC
IL12B AR LOF IL-12, IL-23 mycobacteria, salmonella, CMC
IL12RB1 AR LOF IL-12, IL-23 mycobacteria, salmonella, CMC
IL10 AR LOF IL-10 colitis
IL10RB1 AR LOF IL-10 colitis
IL10RB2 AR LOF IL-10, IL-22, IFN-l colitis
Abbreviations: AR, autosomal-recessive; AD, autosomal-dominant; XR, X-linked recessive; LOF, loss-of-function (null); HPO, hypomorphic; HPR,
hypermorphic (gain of function); DBD, DNA binding domain; TYD, tyrosine domain; SCID, severe combined immunodeficiency; CID, combined immu-
nodeficiency; GHIS, growth hormone insensivity syndrome; colitis, early-onset inflammatory colitis; HIES, hyper-IgE syndrome; CMC, chronic muco-
cutaneous candidiasis; skull and teeth, craniosynostosis, delayed tooth eruption, and supernumary teeth. Asterisk indicates elevated IgE.
aSTAT3-deficient patients lack IL-17 T cells
bSTAT1-hyperactive patients lack IL-17 T cells
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Reviewsignal transduction upon ligand binding is dependent on the acti-
vation of JAK1 and JAK3 (Ghoreschi et al., 2009). In particular,
JAK1 associates with the cytokine-specific receptor subunit,
whereas JAK3 binds to the gc (Russell et al., 1994). This obser-
vation led to the discovery that JAK3 mutations account for an
AR variant of TB+NK SCID in female andmale patients without516 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.IL2RG mutations (Macchi et al., 1995; Russell et al., 1995). The
molecular mechanisms accounting for the impaired develop-
ment of T and NK lymphocytes in patients with defects of gc
and JAK3 signaling were unraveled by studies in humans and
mice showing that IL-7 serves an essential role for T lymphocyte
differentiation (von Freeden-Jeffry et al., 1995; Puel et al., 1998),
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Figure 1. Schematic Representation of the Role of JAK-STAT5
Signaling in Response to Growth Hormone and to Interleukin-2
Left: Binding of growth hormone (GH) to GH receptor (GHR) homodimer trig-
gers activation of the JAK2 kinase that phosphorylates the GHR, creating
docking sites for STAT proteins. Recruitment and JAK2-mediated phosphor-
ylation of only STAT5 is shown, but STAT1 and STAT3 are also activated. In
addition, GH also triggers activation of the PI3K-AKT and Ras-MAPK path-
ways. Phosphorylated STAT5 proteins dimerize and translocate to the nucleus
where they drive activation of target genes. Although both STAT5A and
STAT5B are activated in response to GH, the genes that encode for insulin
growth factor-1 (IGF-1), IGF binding protein 3 (IGFBP3), and the acid labile
subunit of IGF-like binding protein (IGFALS) are under the direct control of
STAT5B, and their expression is markedly repressed in STAT5B-mutated
patients. This results in severe growth failure.
Right: Binding of interleukin-2 (IL-2) to its high-affinity receptor comprising
IL-2Ra, IL-2Rb, and IL-2Rg chains promotes activation of JAK1 and JAK3
proteins and recruitment of STAT3 and STAT5 to the phosphorylated IL-2R
chains. PI3K-AKT and the Ras-MAPK pathways are also activated. STAT5A
and STAT5B are phosphorylated and form homo- and heterodimers that
translocate to the nucleus. Genes that are directly controlled by STAT5B and
whose expression is significantly reduced in STAT5B-mutated patients
include FOXP3 (which promotes development and function of Treg cells),
IL2RA (which favors T cell activation), and the genes that encodes for anti-
apoptotic factors Bcl-2 and Bcl-xL. Failure to activate these genes in response
to IL-2 explains the association of immunodeficiency and immune dysregu-
lation in patients with STAT5B deficiency.
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2000; Lodolce et al., 1998).
The identification of patients with gc and JAK3 defects pre-
ceeded the generation of mice lacking the corresponding genes
(Cao et al., 1995; DiSanto et al., 1995; Nosaka et al., 1995; Park
et al., 1995). Thesemice had a TBNK phenotype, indicating a
requirement for gc-JAK3 signaling in B cell development in mice
but not in humans. The generation of circulating B lymphocytes
in humans is not disturbed by defects in gc and JAK3 signaling,
but the B cells produced harbor intrinsic abnormalities, with
impaired class-switch recombination and defective antibody
production (Buckley, 2010; White et al., 2000). The molecular
basis of B cell-autonomous functional abnormalities in patients
with defects of gc and JAK3 signaling has been recently unrav-
eled. T follicular helper (Tfh) cells secrete IL-21, a potent inducer
of proliferation, Ig isotype switching, plasma cell generation, andAb secretion by human B cells (Vinuesa et al., 2005; Pe`ne et al.,
2004). The binding of IL-21 to a heterodimeric receptor
composed of IL-21R and gc induces activation of the JAK-
STAT pathway. In particular, IL-21-induced STAT3 activation
results in the upregulation of PRDM1 (encoding BLIMP-1) and
XBP1, which are required for plasma cell generation (Diehl
et al., 2008; Avery et al., 2010). In vitro stimulation of X-SCID
and JAK3-deficient B cells with CD40 ligand (CD40L) and IL-21
does not induce proliferation, plasmablast differentiation, or
Ab secretion, strongly suggesting that IL-21 is the primary
gc-dependent cytokine required for the maturation of human
Ab responses (Recher et al., 2011). Studies of infants with
SCID have thus provided insight into the essential role played
by gc and JAK3 signaling in the development of T and NK cells
and in the function of B cells.
Whereas null mutations in IL2RG and JAK3 are responsible
for SCID, hypomorphic mutations in the same genes may
cause other immunodeficiencies, ranging from life-threatening
Omenn syndrome to milder combined immunodeficiencies
(Candotti et al., 1997; Notarangelo et al., 2000; Chen et al.,
2000; Puck et al., 1997). Mutations in the intracytoplasmic tail
of gc allowing residual JAK3 binding have been associated
with a delay in the appearance and gradual decline of circulating
T cells (Schmalstieg and Goldman, 2002). The development of
autologous T cells has also been reported in patients with
JAK3 mutations partially permissive for JAK3 expression and
for JAK3 and STAT5 phosphorylation (Candotti et al., 1997).
The autologous T cells that develop in such patients display an
activated phenotype and a restricted TCR repertoire indicative
of very low levels of thymopoiesis and homeostatic proliferation
(Mella et al., 2000; Brugnoni et al., 1998). However, the R222C
mutation in the intracytoplasmic tail of gc is associated with
normal numbers of circulating T lymphocytes, a normal poly-
clonal T cell repertoire, and normal thymus morphology (Sharfe
et al., 1997b; Poliani et al., 2009). Some gc mutations may thus
be permissive for IL-7-mediated signaling and, hence, for normal
thymic T cell development. However, T cells carrying the R222C
gc mutation bind IL-2 much less strongly than wild-type T cells,
thus accounting for the patients’ immunodeficiency and infec-
tious diseases (Sharfe et al., 1997a). Other patients have been
identified in whom hypomorphic mutations in the IL2RG, IL7R,
and JAK3 genes are even associated with prominent clinical
features of immune dysregulation, including lymphoproliferation
and autoimmunity (Frucht et al., 2001). In one such patient with
residual levels of JAK3 protein, the stimulation of circulating T
lymphocytes with IL-2 in vitro led to normal proliferation, but
no induction of Fas ligand (FasL) expression (Frucht et al.,
2001). Observations in patients with mutations of the IL2RA
and STAT5B genes neatly confirm the critical role played by
IL-2 in immune homeostasis.
Inborn Errors of STAT5B, at the Crossroads of
Immunodeficiency and Immune Dysregulation
In 1997, Sharfe et al. described an infant with severe bacterial,
viral, and fungal infections (Sharfe et al., 1997a). Counts of autol-
ogous T lymphocytes were moderately low, T cells displayed a
weak proliferative response to mitogens in vitro, and the patient
displayed no rejection of an allogeneic skin graft. However,
unlike children with SCID, the patient not only had circulatingImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 517
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and autoimmune primary biliary cirrhosis (Aoki et al., 2006).
The disease was caused by a homozygous mutation of the
IL2RA gene, which prevented expression of IL-2Ra (CD25)
(Table 1; Figure 1; Sharfe et al., 1997a). Ten years later, Caudy
et al. (2007) described another child with biallelic IL2RA gene
mutations and a history of severe viral infections, autoimmune
enteropathy, lymphoproliferation, insulin-dependent diabetes,
autoimmune neutropenia, and eczema. The clinical phenotype
of these two patients included features of both combined immu-
nodeficiency and severe autoimmunity, reminiscent of immune
dysregulation-polyendocrinopathy-enteropathy-X-linked (IPEX)
syndrome, an XR disorder caused by mutations of the FOXP3
gene, which is critically required for the development and func-
tion of CD4+CD25hi T regulatory (Treg) cells (Wildin et al., 2001;
Bennett et al., 2001). The association of immunodeficiency and
autoimmunity in patients with CD25 deficiency reflects the
biological role of IL-2-mediated signaling. In fact, interaction of
IL-2 with its high-affinity receptor, composed of IL-2Ra,
IL-2Rb, and gc, is important both for the activation of effector
CD4+ and CD8+ T cells and for the generation of Foxp3+ induced
Treg (iTreg) lymphocytes from naive peripheral T lymphocytes
(Davidson et al., 2007). Moreover, CD25 deficiency impairs
survival and the fitness of mature nTreg cells in mice (Fontenot
et al., 2005; D’Cruz and Klein, 2005).
In 2003, Kofoed et al. (2003) described a patient with short
stature and growth hormone (GH) insensitivity syndrome
(GHIS), facial dysmorphism, severe infections, and lymphoid
interstitial pneumonitis, with a homozygous missense mutation
in the STAT5B gene, which encodes a key component of the
IL-2R signaling pathway. Several other patients with biallelic
STAT5B mutations have since been reported (Nadeau et al.,
2011), in whom GHIS was associated with susceptibility to
various infections, autoimmune manifestations, and eczema.
Human STAT5A and STAT5B are very similar (>90% identity) in
terms of their cDNA and protein product sequences, suggesting
that they may have been generated by gene duplication.
However, the STAT5A and STAT5B proteins differ in the last
six amino acids of the DNA-binding domain and in 20 amino
acids of the transactivation domain. These differences have
important biological and clinical implications, as demonstrated
by the identification of STAT5B-deficient patients. The interac-
tion of GH with its receptor (GHR) triggers JAK2 activation and
STAT5B phosphorylation, leading to the production of insulin
growth factor 1 (IGF-1), a key factor for body growth (Figure 1).
Patients with GHR deficiency display the same extrahematolog-
ical signs as STAT5B-deficient patients, with postnatal growth
retardation and GH insensitivity (Duquesnoy et al., 1994; Ayling
et al., 1997). By contrast, mice lacking Stat5b present a loss of
sexually dimorphic body growth, such that Stat5b/ males
are similar in size to wild-type females, although wild-type males
are much larger (Udy et al., 1997).
STAT5B-deficient patients also display various autoimmune
and allergic signs, including autoimmune thyroiditis, idiopathic
thrombocytopenic purpura, lymphocytic interstitial pneumonitis,
and severe eczema (Kofoed et al., 2003; Nadeau et al., 2011;
Bernasconi et al., 2006; Hwa et al., 2011; Pugliese-Pires et al.,
2010). Individual targeting of the Stat5a and Stat5b genes in
mice is not associated with significant immune abnormalities518 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.(Udy et al., 1997; Liu et al., 1997). By contrast, Stat5a, Stat5b
double-deficient (Stat5a/Stat5b/) mice have very small
numbers of Treg cells in both the thymus and the periphery
(Antov et al., 2003; Burchill et al., 2003; Yao et al., 2007), leading
to signs of autoimmunity and lymphocytic infiltration in multiple
target organs (Snow et al., 2003). These data are consistent
with the role of Stat5 in the IL-2-induced upregulation of Foxp3
(Murawski et al., 2006). The very small number of CD4+CD25hi
Foxp3+ cells and the impairment of their function in STAT5B-
deficient patients (Cohen et al., 2006) may therefore result
from impaired IL-2 signaling, accounting for the signs of immune
dysregulation associated with the disease, which are clinically
related to those seen in CD25-deficient patients. These patients
also display severe infections. So, what is themechanism under-
lying this immunodeficiency? Higher rates of T lymphocyte
apoptosis are observed only in mice lacking both Stat5a and
Stat5b (Behbod et al., 2003). Nevertheless, an increase in T
lymphocyte apoptosis may contribute to the T cell lymphopenia
observed in STAT5B-deficient patients. Defects of effector
T cells may therefore account for the patients’ broad and
profound susceptibility to infections. These observations indi-
cate that Stat5a and Stat5b play largely redundant roles in the
development and function of the immune and endocrine
systems in mice, whereas STAT5B has unique, nonredundant
functions in growth and immunity in humans.
Inborn Errors of STAT1 Immunity: Loss-of-Function and
Gain-of-Function Alleles Reveal a Double-Edged Sword
Mutations inSTAT1were first identified in studies of patients with
Mendelian susceptibility to mycobacterial diseases (MSMD),
who are prone to clinical disease caused by weakly virulent
mycobacterial species, such as Bacille Calmette-Gue´rin (BCG)
vaccines and environmental mycobacteria (Figure 2; Table 1;
Casanova and Abel, 2002). They are also prone to tuberculosis
and salmonellosis, and, more rarely, to other infections caused
by intramacrophagic bacteria, fungi, and parasites. The first
genetic studies, carried out between 1996 and 2000, implicated
the IFNGR1 and IFNGR2 genes, encoding the two chains of the
IFN-g receptor (Table 1; Figure 2). Allelic heterogeneity at the
IFNGR1 locus defined four forms of IFN-gR1 deficiency,
including two forms of complete and two forms of partial defi-
ciency (Dorman et al., 2004). There is also allelic heterogeneity
at the IFNGR2 locus, with at least three forms of disease (Vogt
et al., 2008). The narrow range of infectious diseases in these
patients was surprising, given the broader susceptibility
observed in the mouse model (van den Broek et al., 1995),
although it gradually became apparent that pathogens other
than Mycobacterium and Salmonella posed a threat to these
patients (Dorman et al., 2004; Vinh et al., 2009).
The disorder is intrinsic to the hematopoietic lineage, because
mycobacterial disease can be cured by HSCT in both mice and
humans (Rottman et al., 2008; Roesler et al., 2004). However, it is
unclear whether IFN-g is required to activate T cells or phago-
cytes, or both, during the course of mycobacterial infection
and whether its activation of T cells results indirectly in activation
of phagocytes. The intramacrophagic nature of most of the
pathogens seen in these patients suggests that human IFN-g
functions more as a macrophage-activating factor than as an
antiviral interferon. It has also been shown that human IL-12,
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Figure 2. Inborn Errors in the IL-12-IFN-g Pathway Underlie
Mendelian Susceptibility to Mycobacterial Diseases
Schematic diagram of cytokine production and cooperation between phago-
cytes and dendritic myeloid cells and NK and T lymphocytes. The IL-12-IFN-g
circuit, the CD40-CD40L pathway, and the oxidative burst (mediated in part by
CYBB-encoded gp91, a component of the NADPH phagocyte oxydase) are
crucial for protective immunity against mycobacterial infection in humans.
Mutations in IFNGR1 or IFNGR2, encoding the ligand-binding and associated
chains of the IFN-gR, impair cellular responses to IFN-g. Likewise, heterozy-
gous dominant-negative mutations in STAT1 impair IFN-g but not IFN-a and
IFN-b responses. Mutations in IL-12p40 or IL-12Rb1 impair IL-12-dependent
induction of IFN-g. Mutations in CYBB that selectively impair the respiratory
burst in monocyte-derived macrophages are associated with MSMD.
Heterozygous dominant-negative mutations in IRF8 impair the development
of IL-12-producing CD11c+CD1c+ DCs. Proteins for which mutations in the
corresponding genes have been identified and associated with MSMD are
shown in red. The allelic heterogeneity is described in Table 1.
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factor, as shown by the fact that patients with IL-12p40 (J.-L.C.,
data not shown) or IL-12Rb1 (de Beaucoudrey et al., 2010) defi-
ciency display MSMD with poor production of IFN-g by both NK
cells and T cells. The nature of the phagocytic cells producing
IL-12 in this process remains unclear, although MSMD patients
with AD IRF8 deficiency lack a potent IL-12-producing leukocyte
subset, the CD1c+CD11c+ dendritic cells (Hambleton et al.,
2011). The genes controlling the microbe-induced production
of IL-12 by phagocytes in this process have remained elusive.
However, the T cell-dependent, CD40-dependent induction of
IL-12 has been shown to be important in this process, as shown
by the fact that this pathway is disrupted in patients with an XR
form of MSMD as a result of specific mutations in the NEMO
genewhereasmost other NF-kBpathways are intact (Filipe-San-
tos et al., 2006; Bustamante et al., 2011b).
In macrophages, IFN-g controls the constitutive and inducible
expression of a wide range of genes. The IFN-g-inducible target
genes in leukocytes, including those operating specifically in
macrophages in the control of mycobacteria, remain to be deter-
mined. However, clues to the identity of these targets were
provided serendipitously by the discovery of MSMD-causing
mutations in CYBB, which encodes the gp91 subunit of the
phagocyte NADPH oxidase.CYBB alleles selectively deleteriousin monocyte-derived macrophages, but not in monocytes and
granulocytes, were found in two kindreds with another XR form
of MSMD (Bustamante et al., 2011a). This observation suggests
that CYBB and perhaps other genes controlling the respiratory
burst may be key targets of IFN-g in host defense against tuber-
culous mycobacteria. IFN-g target genes must, in any case, be
STAT1 dependent, because various heterozygous mutations of
STAT1 were shown, from 2001 onward, to be associated with
the impairment but not abolition of IFN-g responses and
MSMD (Dupuis et al., 2001; Sampaio et al., 2012). This finding
was surprising, because STAT1 is also required for responses
to IFN-a and IFN-b. Human STAT1 was the first member of the
STAT family to be identified as a key molecule required for
cellular responses to IFN-a and IFN-b (Schindler et al., 1992),
and its role in this and IFN-g pathways has been clearly
described in both human and mouse cells (Stark et al., 1998).
The STAT1 alleles found in these MSMD patients are intrinsically
null for both signaling pathways: the activation of STAT1 homo-
dimers (GAF) and STAT1-STAT2-IRF9 heterotrimers (ISGF3).
However, they were dominant for GAF activation (by negative
dominance) but recessive for ISGF3 activation (without negative
dominance and evenwithout haploinsufficiency) in heterozygous
cells. In other words, heterozygosity for the STAT1 mutations
resulted in a normal response of the patients’ cells to IFN-a
and IFN-b (for ISGF3) but not to IFN-g (for GAF), accounting for
the patients displaying MSMD but no viral phenotype.
Viral diseases have not been documented in patients with AD
MSMD carrying STAT1 mutations and have been reported in
only a few patients carrying IFNGR1 or IFNGR2 mutations (Dor-
man et al., 2004). The observation that STAT1 alleles may
underlie MSMD without susceptibility to viral diseases was
confirmed indirectly in 2003 by the identification of the first
patients with an AR form of complete STAT1 deficiency (Dupuis
et al., 2003). These patients display overt susceptibility to both
mycobacterial and viral infections. Their cells do not respond
either to IFN-g or to IFN-a and IFN-b. Unlike MSMD patients
with STAT1 mutations, whose outcome is favorable, these
patients died in the absence of HSCT. The underlying defect
was subsequently shown to be broader, impairing responses
to IFN-l and IL-27 (Chapgier et al., 2009). Other patients with
a similarly broad and profound susceptibility to viral infections
have since been described (Chapgier et al., 2006; Vairo et al.,
2011). Hypomorphic alleles underlie partial forms of AR STAT1
deficiency with a milder bacterial and viral phenotype (Averbuch
et al., 2011; Kristensen et al., 2011; Chapgier et al., 2009; Kong
et al., 2010). Patients with either form of AR STAT1 deficiency are
broadly susceptible to viruses, including herpes simplex virus-1
(HSV-1) infections, which may cause HSV-1 encephalitis (HSE)
(Figure 3; Table 1; Sancho-Shimizu et al., 2011; Dupuis et al.,
2003). The existence of a STAT1-independent IFN-a- and
IFN-b-responsive pathway, together with the action of antiviral
molecules other than IFNs, might account for the control of at
least some viral infections in patients lacking STAT1 (Chapgier
et al., 2006). Conversely, the contribution of IFN-a and IFN-b
and of IFN-l to the viral phenotypes seen in patients bearing
STAT1 mutations is unknown, because no patient lacking either
the IFN-a and IFN-b receptor or the IFN-l receptor has been
described (Zhang et al., 2008). However, IL-10Rb-deficient
patients would be expected to be unresponsive to IFN-l, butImmunity 36, April 20, 2012 ª2012 Elsevier Inc. 519
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Figure 3. Inborn Errors of TLR3-Dependent IFN-a, IFN-b, and IFN-l
Immunity Underlie Childhood Herpes Simplex Virus 1 Encephalitis
Schematic representation of the production of and response to IFN-a and
IFN-b and IFN-l in anti-HSV-1 immunity in the central nervous system (CNS),
based on the genetic dissection of children with HSE. Likemost viruses, HSV-1
produces dsRNA intermediates during its replication. TLR3 is an endosomal
transmembrane receptor for dsRNA. The recognition of dsRNA by TLR3
induces activation of the IRF-3 and NF-kB pathways via TRIF, leading to IFN-a
and IFN-b and/or IFN-l production. TLR3, UNC-93B, TRIF, TRAF3, and NEMO
deficiencies are all associated with impaired IFN-a and IFN-b and/or IFN-l
production and predisposition to HSE in the course of primary infection by
HSV-1. The binding of IFN-a and IFN-b and IFN-l to their receptors induce the
phosphorylation of JAK1 and TYK-2, activating the signal transduction
proteins STAT1, STAT2, and IRF9. This complex is translocated as a hetero-
trimer to the nucleus, where it acts as a transcriptional activator, binding to
specific DNA response elements in the promoter region of IFN-inducible
genes. STAT1 and TYK2 deficiencies are associated with impaired IFN-a and
IFN-b responses and, for STAT1, impaired IFN-l responses and predisposition
to HSE. Proteins for which genetic mutations have been identified and asso-
ciated with susceptibility to isolated herpes simplex encephalitis (HSE) are
shown in blue. Proteins for which genetic mutations have been identified and
associated with susceptibility to mycobacterial, bacterial, and viral diseases,
including HSE, are shown in green. Proteins for which genetic mutations have
been identified but not associated with susceptibility to infectious diseases are
shown in red. This figure will be revised as new results are obtained with the
genetic and immunological dissection of children with HSE and other viral
diseases.
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Reviewnot IFN-a and IFN-b, and such patients have never yet been
reported to display susceptibility to any particular viral disease
(Glocker et al., 2009). The cells requiring STAT1 to control viruses
have not been identified. The IFN-a, IFN-b, and IFN-l target
genes controlling viruses including HSV-1 have also remained
elusive. The identification of more patients with inborn errors of
IFN-a, IFN-b, and IFN-l immunity, including AR forms of
STAT1 deficiency, should help to define the molecular and
cellular basis of human viral infections.
Surprisingly, a whole-exome sequencing study aiming to
identify genetic etiologies of chronic mucocutaneous candidi-
asis (CMC) identified patients with AD CMC carrying heterozy-
gous missense mutations affecting the STAT1 coiled-coil
domain (CCD) (Figure 4; Table 1; Liu et al., 2011). A genome-
wide linkage analysis led to the independent identification of
similar mutations in other patients with CMC (van de Veerdonk
et al., 2011). These patients seem to be affected by a broader
range of fungal diseases, as indicated by the fact that the
same STAT1 mutations were recently found in patients with520 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.CMC and disseminated disease caused by Coccidioides immitis
and Histoplasma capsulatum (S.M.H., data not shown). An
explanation for this paradox was provided by the demonstration
that the CMC-causing STAT1 alleles are actually gain of function
(Liu et al., 2011). This observation accounts for the development,
in some patients with CMC, of autoimmune signs, which may
result from enhanced IFN-a and IFN-b immunity (Crow, 2011).
Nuclear dephosphorylation, rather than hyperphosphorylation
in the cytoplasm, is thought to be the principal mechanism
underlying the gain of function of these alleles (Liu et al., 2011).
These alleles have been shown to be both gain of function and
dominant for all cytokines tested: IFN-a and IFN-b, IFN-g, IFN-
l, and IL-27. The CMC phenotype can also be accounted for
by the very poor development of IL-17-producing T cells (Liu
et al., 2011). Indeed, patients with AD IL-17F or AR IL-17RA defi-
ciency are prone to CMC (Puel et al., 2011). The mechanism by
which STAT1 gain-of-function alleles impair the development of
IL-17 T cells remains to be deciphered. One possibility, based on
work in the mouse model, is that IFNs and IL-27 strongly inhibit
the development of IL-17-producing T cells (Chen et al., 2009).
Alternatively, the gain-of-function STAT1 molecules may divert
signals that are normally dependent on STAT3, downstream
from IL-6, IL-21, and IL-23, all of which are potent inducers of
IL-17 T cells (Zhou et al., 2007). The search for new genetic
etiologies of CMC should provide insight into the mechanisms
actually involved. In any case, STAT1 is an example of a human
gene for which loss-of-function mutations have been shown to
cause certain infectious diseases, whereas gain-of-function
mutations cause other infectious diseases.
Inborn Errors of STAT3 Have Hematological
and Extrahematological Consequences
The AD form of hyper-IgE syndrome (HIES), first described as
Job’s syndrome in 1966, is characterized by the triad of eczema
and recurrent staphylococcal skin and lung infections (Davis
et al., 1966). In 1972, IgE elevation was added to the syndrome
(Buckley et al., 1972). Closer examination also revealed that
these patients had somatic features, such as a characteristic
facial appearance, for which simple immunologic explanations
were unconvincing. The range of infections in these patients is
relatively limited, restricted principally to a number of bacteria
and fungi, including Staphylococcus aureus and Candida
albicans. High IgE levels (Buckley et al., 1972; Buckley and
Becker, 1978) and the impairment of antibody synthesis (Sheerin
and Buckley, 1991; Avery et al., 2010) and neutrophil chemotaxis
(Buckley and Becker, 1978; Donabedian and Gallin, 1983) in
some patients have been documented, but T cell function was
normal (Buckley and Becker, 1978). The transmission of HIES
in multiplex families suggested an AD mode of inheritance
(Buckley and Becker, 1978; Grimbacher et al., 1999).
The seminal observation of TYK2 deficiency with atopy, staph-
ylococcal disease, and high levels of IgE prompted detailed
exploration of the IL-6 signaling pathway in patients with AD
HIES (Minegishi et al., 2006), leading to the identification of domi-
nant-negative STAT3 mutations as the cause of AD HIES
(Figure 5; Table 1; Minegishi et al., 2007; Holland et al., 2007).
The clinical penetrance of these alleles appeared to be
complete; sporadic cases were caused by de novo mutations.
Most of the HIES-causing mutations in STAT3 are missense or
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Figure 4. Inborn Errors of IL-17 Immunity
Underlie Chronic Mucocutaenous
Candidiasis
Upon C. albicans recognition via various cell
surface receptors, adaptor molecules SYK and
CARD9 mediate the induction of proinflammatory
cytokines by myeloid and epithelial cells. Proin-
flammatory cytokines, such as IL-6, IL-21, or
IL-23, activate T lymphocytes via STAT3, resulting
in their differentiation into IL-17-producing T cells.
These cells constitute a major component of the
immune defense againstC. albicans, as mutations
in IL-17F or IL-17RA underlie CMC. Gain-of-
function mutations in STAT1 inhibit this differen-
tiation bymechanisms that have remained elusive.
Enhanced stimulation via IFN-a, IFN-b, IFN-g,
IFN-l, and IL-27 might be responsible for this
phenotype. The molecule TYK2 is known to act
upstream of STAT1 and STAT3. It is unclear
whether patients with AR TYK2 deficiency display
CMC. Proteins represented in blue are mutated in
patients with CMC only. Proteins represented in
red are mutated in patients with CMC and other
infections.
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Reviewin-frame deletions in the SH2 or DNA-binding domains. The
mutations are intrinsically loss of function but result in inhibition
of STAT3 function in a dominant-negative manner (Minegishi
et al., 2007). Homozygous Stat3 deficiency led to the death of
deficient mouse embryos, whereas heterozygotes had no re-
ported phenotype. Therefore, Stat3 was necessary for survival,
but there was no overt haploinsufficiency (Takeda et al., 1997).
This finding is consistent with the observation that dominant-
negative STAT3 mutations decrease STAT3 homodimer activity
to about 25% of the normal level (Minegishi et al., 2007;
Minegishi, 2009). The embryonic lethality of Stat3/ mice has
made it necessary to explore various hematological and extrahe-
matological tissue-specific deletions. These deletions are impor-
tant models for STAT3 function in various tissues but are far from
exact mimics of AD HIES, which is partial and affects all tissues
simultaneously.
STAT3 was discovered on the basis of sequence similarities to
STAT1 andwas initially recognized as a signal transducer for IL-6IL
-6
R
IL
-1
1R
LI
F-
R
O
sM
-R
C
T1
CL
C
CN
TF
gp
13
0
JAKTYK
P
STAT3
STAT3
Mutant
STAT3
P
P
STAT1
Mutant
STAT3
P
P
P
ST
P
TNF-α
IL-12
IFN-γ
IL-10
SOCS1
SOCS3
IL
-1
0R
1
IL
-1
0R
2
γc IL-
21andepidermal growth factor (EGF), but not for IFN-g (Zhonget al.,
1994). STAT3 is directly involved in signaling from a multitude of
hematological and extrahematological receptors, especially
those using the common b chain gp130 (White and Stephens,
2011; Donnelly et al., 2010; Minegishi and Saito, 2011; Tangye
et al., 2009). At least six classes of receptors other than gp130-
dependent receptors are known to activate STAT3, which has
been implicated in the signal transduction pathways involving
gc-dependent cytokines, type I and II interferons, the IL-10 family
of cytokines, IL-12 and IL-23, receptor tyrosine kinases, and
other stimuli (Tangye et al., 2009; O’Shea and Murray, 2008;
O’Shea et al., 2002; Levy and Darnell, 2002). After stimulation
of the cell, JAKs phosphorylate a key tyrosine residue of STAT3
and the resulting phosphorylated STAT3 forms homo- and heter-
odimers that are translocated to the nucleus, where they activate
a complex array of genes, depending on the stimulus and cell
type. There is an extraordinarily high diversity of genes being
regulated by STAT3, in a wide range of cell types and tissues.AT5
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Figure 5. Multiple Receptors Activate the
STAT3 Signaling Pathway
The signaling and inhibitions of STAT3 are shown,
with areas of special emphasis for the dominant-
negative mutants shown. Gray STAT3 depicts
the AD mutant form of the molecule, with each
heterodimer in which it participates being inhibited
from function. The thunderbolts indicate where
a normal function is inhibited. STAT3 is involved
both in IL-10 signal transduction and in IL-10
expression, both of which are affected in Job’s
syndrome.
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ReviewSo, what does the discovery of STAT3 mutations tell us about
the pathogenesis of infectious diseases in patients with AD
HIES? In a murine T cell transfer model, STAT3 is required for
the development of Th17 cell-mediated colitis (Durant et al.,
2010), as a result of the STAT3 dependence of cytokines, which
induce Th17 cell development. The development of IL-17 CD4+
T cells is thus profoundly impaired in patients with HIES (de
Beaucoudrey et al., 2008; Ma et al., 2008; Milner et al., 2008;
Minegishi et al., 2009). The observation of CMC in patients
with AD IL-17F or AR IL-17RA deficiency suggests that the
development of CMC in AD HIES patients results from impaired
IL-17 immunity (Liu et al., 2011; Puel et al., 2011). Interestingly,
heterozygous loss-of-function STAT3 alleles and heterozygous
gain-of-functionSTAT1 alleles are both associatedwith impaired
development of IL-17 CD4+ T cells. Respiratory epithelial cells
and keratinocytes, unlike endothelial cells and fibroblasts, have
been shown to be tightly dependent on IL-17 for the induction
of antimicrobial target genes, probably accounting for CMC
(Minegishi et al., 2009). The observation that patients lacking
IL-17A and IL-17F immunity mostly present with CMC (Puel
et al., 2011) suggests that other mechanisms probably underlie
the pathogenesis of pulmonary lesions in HIES. The develop-
ment of severe staphylococcal diseases in HIES patients, partic-
ularly in the lungs, remains unexplained, because infections of
this type are not observed in patients with other inborn errors
of IL-17 immunity. A high proportion of AD HIES patients were
recently shown to have recurrent episodes of varicella zoster
infection, which was attributed to the impairment of memory
T cells (Siegel et al., 2011). Patients had fewer CD4+ and CD8+
central memory T cells than normal, and these cells displayed
low levels of proliferation in vitro. They also displayed specific
impairment of the control of varicella zoster and Epstein-Barr
viruses but normal control of cytomegalovirus and herpes
simplex virus.
What molecular mechanisms underlie some of the hematolog-
ical and immunological phenotypes not directly related to the
infectious diseases seen in HIES patients? The much higher
risk of aggressive, predominantly B cell lymphomas in patients
with ADHIES (Leonard et al., 2004) is surprising, because consti-
tutive STAT3 gain-of-function somatic mutations are found in
many tumors, including lymphomas (Bowman et al., 2000). The
patients’ B cell anomalies have begun to be unraveled. T follic-
ular helper (Tfh) cells are critical for the formation of germinal
centers, and the differentiation of both Tfh cells and B cells is
controlled by IL-21 (Nurieva et al., 2008; Vogelzang et al.,
2008; Recher et al., 2011). Human IL-21 uses STAT3 and IRF-4
to drive B cell differentiation into plasma cells (Avery et al.,
2010; Kwon et al., 2009). AD HIES patients have very low
numbers of antigen-specific memory B cells despite intact class
switch recombination (Avery et al., 2010; Speckmann et al.,
2008; Meyer-Bahlburg et al., 2012). However, their germinal
centers are relatively normal and the contribution of these B
cell abnormalities to clinical disease remains unclear. B cell
immaturity is strongly linked to the preferential production of
IgE in mice and might explain the IgE elevation in patients (We-
semann et al., 2011). Finally, we must consider atopy. Patients
with AD HIES have normal numbers of nTreg cells with normal
activity, but their ability to respond to IL-10 and the development
of iTreg cells are impaired, potentially accounting for the atopic522 Immunity 36, April 20, 2012 ª2012 Elsevier Inc.and inflammatory complications that are so common in this
disease (Saito et al., 2011). Residual IL-10 responses, whether
dependent on or independent of STAT3, may account for the
inflammatory diseases of HIES patients being less severe
than those of patients with deficiencies of IL-10, IL-10RA, or
IL-10RB (Glocker et al., 2009, 2010). Atopy is exacerbated by
a high skin staphylococcal burden and improved by the control
of these bacteria with antibiotics or topical antiseptics.
Many primary immunodeficiencies have extrahematological
aspects (Al-Herz et al., 2011), but the variety and complexity of
such manifestations in HIES were initially confusing and the
identification of STAT3 as the morbid gene has been startling.
One of the most striking features of AD HIES is the characteristic
pulmonary cyst formation after pneumonia. The need for lung
epithelial cells to migrate, orient, and ciliate after injury are
severely impaired in mice with lung epithelium-restricted
STAT3 and gp130 deficiencies (Kida et al., 2008). STAT3 also
regulates the expression of matrix metalloproteinases (MMPs),
which are involved in tissue response to injury and are aberrant
in HIES (Sekhsaria et al., 2011). Arterial remodeling and inflam-
mation are tightly controlled by the TNF-a-induced production
of RANTES, which is dependent on both NF-kB and STAT3,
ultimately resulting in vascular smooth muscle cell proliferation
and atherosclerosis (Kovacic et al., 2010). Whether this explains
the high rate of coronary artery tortuosity and aneurysm forma-
tion seen in HIES patients and the associated aneurysms in
cerebral vessels and lesions in brain white matter (Freeman
et al., 2011; Chandesris et al., 2011) remains to be determined.
A similar process may operate in CMC patients heterozygous
for gain-of-function STAT1 mutations, who are also prone to
cerebral aneurysms (Liu et al., 2011). Chandesris et al. (2011)
demonstrated a direct link between STAT3 and aneurysm forma-
tion in mice. Interestingly, HIES patients are not at high risk of
atherosclerosis, suggesting that STAT3 deficiency causes arte-
rial aneurysm for reasons distinct from atherosclerosis (Cohen
and O’Gara, 2008; J.-L.C., data not shown). Finally, the reasons
for the delayed primary dental deciduation and craniosynostosis
observed in HIES patients remained a mystery for many years.
The recent identification of families with isolated mutations in
the gp130-associated IL-11RA who have a similar phenotype
(Nieminen et al., 2011) suggests that the IL-11 pathway is indeed
impaired in STAT3-deficient patients and that this defect may
explain some of the craniofacial aspects of Job’s syndrome.
Inborn Errors of TYK2 Immunity: Clinical and
Immunological Phenotypes; Progress to Date
We arrived at a more complicated page in the story of human
inborn errors of the JAK-STAT pathway in 2006, with the descrip-
tion of a Japanese patient with AR TYK2 deficiency (Figures 2, 3,
4, and 5; Table 1; Minegishi et al., 2006). Consistent with a
previous classification of HIES on the basis of mode of inheri-
tance into two distinct forms, AD and AR (Renner et al., 2004),
TYK2 deficiency was considered to be an AR genetic etiology
of HIES. This was based on the observation that the patient lack-
ing wild-type TYK2 had atopy, was susceptibility to cutaneous
staphylococcal diseases, and had high serum concentrations
of IgE. However, like MSMD patients, this patient was also
susceptible to intramacrophagic bacteria, such as BCG and
Salmonella in particular. This infectious phenotype is not
Immunity
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negative STAT3 mutations (Grimbacher et al., 1999; Minegishi,
2009; Freeman and Holland, 2010). The TYK2-deficient patient
also developed viral diseases, including recurrent cutaneous
herpes simplex virus disease in particular, which is not a charac-
teristic feature of HIES. However, patients with STAT3mutations
have also recently been reported to be prone to viral diseases
that reactivate from latency, including VZV and EBV, and this
susceptibility has been attributed to an exhaustion of their
memory T cells rather than the impairment of IFN responses (Sie-
gel et al., 2011). Thus, clinically, this TYK2-deficient patient may
be considered to have HIES. However, the absence of the
multiple, nonhematological, developmental signs of AD HIES
and the presence of intramacrophagic infections suggest that
TYK2 deficiency may be an AR genetic etiology of a phenotype
related to but different from HIES.
Consistent with this view, a Turkish patient was recently
found to have TYK2 deficiency with no hematological or extrahe-
matological features of HIES (Kilic et al., 2012). This adult patient
had never developed staphylococcal disease and had no history
of atopy, and his serum IgE titers never reached the values seen
in HIES patients, including the previously described TYK2-
deficient patient. However, like this previous patient, he was
susceptible to the reactivation of cutaneous viral infections,
with recurrent varicella zoster virus lesions. He was also prone
to intramacrophagic bacterial infections. Indeed, he initially pre-
sented with disseminated BCG disease and later suffered from
neurobrucellosis, which resolved but resulted in cognitive
impairment. These two TYK2-deficient patients also differed
somewhat in terms of fungal susceptibility: the Japanese patient
displayed mild CMC, which was not documented in the Turkish
patient. With only two TYK2-deficient patients displaying such
overlapping but nonetheless different phenotypes, it is difficult
to delineate the clinical hallmark of TYK2 deficiency.
The biological role of human TYK2 in various pathways was
investigated in cells from the Japanese patient. TYK2 is a
member of the JAK kinase family (Velazquez et al., 1992), but it
has proved difficult to determine its precise role in various
signaling pathways in the mouse model (Strobl et al., 2012).
TYK2 seems to be nonredundant in mice for cellular responses
to receptors for at least two classes of cytokines, including
IL-12 and IFN-a and IFN-b (Shimoda et al., 2000; Karaghiosoff
et al., 2000). Residual responses to mouse cytokines were
observed in the complete absence of TYK2. The cells of the
Japanese patient did not respond to IFN-a and IFN-b, providing
a plausible basis for the susceptibility to viral infection observed
in the two patients. The cells of this patient also failed to respond
to IL-12, possibly accounting for vulnerability to Salmonella,
Mycobacterium, and Brucella. These responses were rescued
by transfection with wild-type TYK2. TYK2-deficient patients
can therefore be seen almost as immunological and clinical phe-
nocopies of patients with a partial form of AR STAT1 deficiency,
displaying impaired but not abolished IFN-g and IFN-a and IFN-b
immunity and a particular susceptibility to diseases caused by
intracellular bacterial and viral pathogens (Kong et al., 2010;
Chapgier et al., 2009). The cellular response to other members
of the IFN-a and IFN-b and of the IL-12 receptor families has
not been investigated. The Japanese TYK2-deficient patient
also had impaired responses to IL-10 (Saito et al., 2011; Mine-gishi et al., 2006), but neither he nor the Turkish patient displayed
the early-onset, severe colitis observed in patients with IL-10,
IL-10R1, and IL-10R2 deficiencies (Glocker et al., 2009, 2010),
suggesting that there are residual, TYK2-independent responses
to IL-10. The atopy seen in the Japanese patient may result from
an impaired but not abolished IL-10 response (Saito et al., 2011).
Cellular responses to IFN-l and other members of the IL-10
family were not tested. Finally, the Japanese patient responded
poorly to IL-6; responses to the other members of the IL-6 family
of cytokines were not tested. Overall, the atopy, staphylococcal
disease, and high IgE titers documented in the Japanese patient
and their absence in the Turkish patient remain largely unex-
plained. In any case, the lack of extrahematological manifesta-
tions in the two TYK2-deficient patients implies that the
STAT3-dependent pathways responsible for such phenotypes,
such as the IL-11 pathway, are not TYK2 dependent (Nieminen
et al., 2011).
Concluding Remarks
The characterization of inborn errors of JAK3, TYK2, STAT1,
STAT5B, and STAT3 in humans has provided answers to key
questions about the function of these molecules. Some of these
answers preceded or confirmed observations in mouse or
human cells in vitro and observations in mice in vivo. More
surprising observations include the association of gain-of-func-
tion STAT1 mutations with AD CMC, as a result of the inhibition
of the development of IL-17-producing T cells, the profound
endocrinological and immunological phenotype of STAT5B-defi-
cient patients, and the association of loss-of-function STAT3
mutations with ADHIES, a complex disorder combining hemato-
logical and extrahematological signs. The dissection of clinical
and immunological phenotypes associated with germline muta-
tions in related receptors engaging JAKs and STATs has been
essential to decipher the pathogenesis of the disorders of these
five genes. For example, we would not understand some dental
and skeletal manifestations of AD HIES if patients with AR
IL-11RA deficiency had not been identified, and the immune
dysregulation of STAT5B-deficient patients would not be under-
stood if AR IL-2RA deficiency had not been identified. The
identification of other inborn errors of immunity, affecting recep-
tors that do not engage JAKs and STATs, has also been illumi-
nating. We would not understand the basis of CMC in patients
with gain-of-function STAT1 mutations if we had not identified
patients with inborn errors of IL-17F or IL-17RA. In turn, the
discovery of germline mutations in human JAK and STAT genes
has raised new questions. Many of the immunological and
clinical phenotypes seen in these patients remain unexplained
at the molecular and cellular levels. For example, we still do
not understand the molecular and cellular basis of staphylo-
coccal abscesses in patients with HIES. The advent of whole-
exome and whole-genome sequencing will, undoubtedly,
facilitate the discovery of new inborn errors of known and
unknown genes, shedding light on the pathogenesis of the disor-
ders involving these five genes. It is also probable that germline
mutations in the remaining two JAKs (JAK1 and JAK2) and the
remaining three STATs (STAT2, STAT4, and STAT5A) will soon
be discovered. Despite 20 years of outstanding research on
these molecules, it remains difficult to predict, with any degree
of confidence, the phenotypes of the corresponding patients.Immunity 36, April 20, 2012 ª2012 Elsevier Inc. 523
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ReviewWith an expanding world population that has already reached
seven billion people, increasingly efficient andwidespread ‘‘phe-
notyping’’ by physicians worldwide, a mean mutation rate in the
germline of 108, a human genome of 3.2 billion bp, 2% of
which corresponds to 25,000 RNA and protein genes, and a cost
of whole-genome sequencing already approaching $1,000, you
do not need to be a mathematician to work out that it is now
only amatter of years, decades at most, until germline mutations
in most of the human genes controlling JAK- and STAT-depen-
dent responses will have been collected and analyzed. Exciting
times lie ahead.
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